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Author summary
Interleukin-2 (IL-2) has been used in immunotherapy for cancer and autoimmunity and its beneficial effect has been linked to the modulation of immune responses, which partly relies on a direct effect on Tregs populations. In this study, we assessed the role of IL-2 in HIV infection and investigated whether its use as an adjuvant with therapeutic vaccination, impacts on HIV-specific responses. We show that IL-2 administration increased HIV-specific CD4 
Introduction

CD4
+ regulatory T cells (Tregs) are central in maintaining peripheral tolerance and constitute the most important extrinsic inhibitory mechanism that control T-cell responses (reviewed in [1] Tregs, best at regulating targeted immune responses, can be identified by the expression of costimulatory molecules such as CD134 (OX40) [5, 6] or CD137 (4-1BB) [7, 8] . 
FoxP3
+ were slightly increased, probably reflecting restoration of CD4 + T-cell compartment [9] . However, Tregs subsets dynamics and the particular role played by each subset during chronic infection are still unclear.
Targeting Tregs subsets to shift the balance between tolerance and immunity in the clinic remains challenging. To this end, the use of recombinant interleukin 2 (rIL-2) has been beneficial as several successes of low-dose rIL-2 therapy in animal models of autoimmune pathology [10] [11] [12] [13] [14] and human clinical studies in hepatitis C virus induced vasculitis, chronic graft-versus-host disease (GVHD), Type1 Diabetes (T1D), systemic lupus erythematosus (SLE), and Alopecia areata [15] [16] [17] [18] [19] [20] [21] have been reported. These successes led to other clinical trial studies, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, Behcet's disease, Crohn's disease and ulcerative colitis (TRANSREG, clinicalTrials.gov NCT01988506). The advantageous function of low-dose rIL-2 in this context has been linked to the expansion of Tregs that play a major role in controlling immune responses and establishing tolerance [22] .
In cancer immunotherapy, high-dose intermittent rIL-2 therapy has increased long-term survival for some patients with metastatic renal cell carcinoma [23] and rIL-2 therapy alone or in combination with a peptide vaccine has resulted in clinical improvement for patients with metastatic melanoma [24, 25] . However, the use of rIL-2 to enhance immune restoration in infectious diseases such as in human immunodeficiency virus (HIV-1) infection did not have similar success. Indeed, two major clinical trial studies, SILCAAT and ESPRIT, have been conducted to expand the CD4 + T-cell pool in HIV-1-infected patients and despite a substantial and sustained increase in the CD4 count as compared with antiretroviral therapy (HAART) alone, rIL-2 plus HAART yielded no clinical benefit [26] . These disappointing results were explained by the expansion of two distinct CD4 [27] . However, when continuous IL-2 administration has been used as an adjuvant along with therapeutic vaccination and antiretroviral treatment, in simian immunodeficiency virus (SIV) infected macaques, the results showed increased SIVspecific CD8 T-cell responses and resulted in decreased viral load (VL) [28, 29] . In humans, greater improvement was seen in one trial (ANRS 093), where patients were randomized to continue either HAART alone or to receive therapeutic vaccines (ALVAC-HIV and Lipo-6T) followed by 3 cycles of subcutaneous IL-2 [30, 31] . The results showed that therapeutic immunization combining ALVAC-HIV and Lipo-6T vaccines followed by IL-2 administration, induced sustained and broad CD4 T-cell immune responses to HIV antigens in chronically HIV-infected patients, that correlated with a partial control of viral replication following treatment interruption (TI) [30, 31] . In this ANRS 093 follow-up study, we aimed to comprehensively analyse changes in the phenotype and function of Tregs subsets and hypothesized that by using IL-2 as an adjuvant along with therapeutic vaccination, we may affect distinctively peripheral global CD4 + CD25 
Results
Therapeutic immunization strategy
This clinical trial is part of the ANRS 093 randomized study. As detailed in the methods section and summarized in Fig 1, HAART treated chronic HIV-infected subjects received two different vaccines: four shots of recombinant ALVAC-HIV (vCP1433) and HIV LIPO-6T (HIV-1 lipopeptides + TT) or placebo every four weeks, followed by administration of three cycles of subcutaneous IL-2 at 4.5MIU (two injections a day for five days). Cells from 26 HAART treated chronic HIV-infected subjects received two vaccines: recombinant ALVAC-HIV (vCP1433) and Lipo-6T (HIV-1 lipopeptides), followed by administration of three cycles of subcutaneous IL-2. Patients received a schedule of four shots of vaccine or placebo, every four weeks followed by three cycles of IL-2 at 4.5MIU (two injections a day for five days). Eight weeks after the last IL-2 cycle, HAART was stopped and patients' viral load measured. The treatment was reintroduced only if viral load was over 50,000 copies/ml at one measurement or over 10,000 copies/ml at two consecutive measurements.
patients (n = 8 placebo and n = 18 vaccine/IL2) were available amongst the 70 patients included in the ANRS 093 trial. In this study, we focused our analyses on vaccine/IL-2 group patients (n = 18) before (wk0) and after vaccine (wk16) and IL-2 treatment (wk36). Placebo group has not been included in our analyses, apart from Table 1 where vaccine/IL-2 group characteristics were compared to the placebo group. As summarized in the table, patients from both groups showed no difference in CD8 and CD4 cell counts and in nadir CD4 at randomization. Plasma HIV-1 VL (copies RNA/ml) before HAART was higher in the vaccine group. After vaccination (wk36), all but 1 in placebo group had undetectable plasma HIV-1 VL and CD8 cell count was lower in vaccine group. After treatment interruption (wk40), HIV-1 RNA peak was significantly lower in the vaccine group, and a trend towards a longer time to viral peak rebound was observed in the vaccine group as compared to the placebo group (Table 1) . Fig 2) ), demonstrating the direct effect of IL-2 on both IL-2 receptor α-chain-expressing cell subsets (Fig 2B-2D ). The only exception was the memory CD39 + subset among total memory Tregs that decreased after IL-2 administration (mean ±SEM of 52.5% ±7.06 vs 44.5% ±5.7, p<0.05; Fig 2E) . The comparison in Tregs expansion at wk36 after IL-2 treatment highlights the significant expansion of the naïve Tregs compartment compared to the others ( Fig 2F) .
Subcutaneous injections of IL-2 decrease PD-1 expression in CD4+ and CD8 + T cells
Given that T-cell activation and exhaustion are two major features of chronic viral infections [32] , we assessed these two characteristics using patients' CD4 + and CD8 + T-cells at wk0, wk16 HIV-specific CD4 + T-cell responses were amplified by IL-2 treatment and inversely correlated with VL after treatment interruption + HIV-specific responses induced after vaccination, inversely correlated with viral load rebound after TI [9] . To investigate whether the same applied in ANRS 093 clinical trial where a different vaccine was given, we measured CD4 + Gag-specific responses at wk0, wk16 and wk36 using the "OX40 assay" (reviewed in [1] ). We observed a significant increase in HIV-specific responses only after IL-2 treatment (wk36) (wk16 vs wk36 p<0.02 and wk0 vs wk36 p<0.008, Fig 5B) . This induction was antigen-dependent as only HIV-specific but not CMV-specific responses were affected (Fig 5B  and 5D ). In line with our previous findings, the HIV-specific responses (at wk36) inversely correlated with viral load after treatment interruption (r = -0.7 and p<0.007; Fig 5C) , but this was not the case for CMV-specific responses, which did not show any correlation with HIV viral load after treatment interruption (Fig 5E) . Of note, we did not see any changes in CD4 Negative modulation of HIV-specific Tregs by IL-2 therapy
Results described above showed that IL-2 therapy down-modulated a population of Tregs expressing CD39 + . We have previously shown that by using CD39 and FoxP3 we were able to delineate two populations of antigen-specific CD4
+ T cells with different origin and function, namely Tregs and Teffs (Fig 6A) and [6, 9] and that CD39 + Tregs are potent suppressors of HIV-specific responses in both natural infection and vaccination [9, 34] . Accordingly, we confirm here that frequency of CD39 To describe more thoroughly the phenotype of these cells, we assessed the expression of several putative Tregs markers, such as Helios, CTLA-4 and CD15s, which has recently been reported as a novel marker of highly suppressive Tregs [35] . Our results show that these markers were more abundantly expressed on CD39 (Fig 8B) . ICOS expression was similar in all subsets but Tbet and PD-1 expressions were higher in CD39 + and viral load at resuming ART, at wk36 for p24 and CMV, respectively. Correlations were calculated using spearman correlation coefficients (Prism 5.0, version 5.0d). P values were considered significant when < 0.05. At the same time, we observed after IL-2 therapy a trend for an increase in CD39 -FoxP3 -CD25 + CD134 + effector cell frequency at wk36 compared to wk0 (Fig 6F) . Moreover, an inversed correlation with VL was observed but was not statistically significant ( Fig  6G) . In contrast, the fraction of CD25 
Discussion
Lessons from the previous phase III trials (SILCAAT and ESPRIT) that have been conducted to expand the CD4 + T-cell pool in HIV-1-infected patients and yielded no clinical benefit [26] , were very disappointing which somehow banished the use of rIL-2 in HIV immunotherapy and made the medical community increasingly reluctant to use recombinant cytokines in this context. Greater improvements were seen however, in the ANRS 093 study where patients were randomized to continue either HAART alone or to receive therapeutic vaccination followed by 3 cycles of subcutaneous IL-2 [31] . In this study, we revisited the role of IL-2 in immunotherapy and investigated the dynamics of Tregs subsets in HIV-infected patients receiving therapeutic vaccination combined to IL-2 therapy. We show that while peripheral global CD25 Tregs were inversely correlated with viral load after treatment interruption, which is reminiscent of our recent report [9] . Moreover, we observed a significant decrease in T-cell exhaustion as demonstrated by the down-regulation of PD-1, Tim-3, 2B4 for use as an adjuvant in the context of chronic infections as long as it is used in combination with a vaccine. Moreover, timing and dosing of IL-2 need to be carefully considered for each situation, as previous studies showed that exogenous IL-2 is detrimental during the expansion phase after acute LCMV infection for both CD8 and CD4 virus-specific T cells [36] . Of note, excessive IL-2 during T-cell expansion modulates T-cell differentiation towards terminal effectors, which increases cell death and hampers memory formation, whereas IL-2 administration during contraction led to increased cell survival [36] . Therefore, a careful examination of IL-2 dosing and timing as a means to shift the balance between immunity and tolerance could be the key for future studies. The benefit in using systemic low-dose IL-2 has been reported in several autoimmune disorders [15] [16] [17] [18] [19] [20] [21] . Studies indicated that this approach is well tolerated and the advantageous function of low-dose IL-2 has been linked to the expansion of Tregs in controlling immune responses and establishing tolerance [22] . However, several studies reported that Tregs have an ambiguous role in HIV infection, as they decrease immune activation, which is beneficial for HIV-infected individuals, but they also suppress anti-HIV responses, which is undesirable in such condition (reviewed [1] ). Part of this ambiguity is related to Tregs identification and quantification (reviewed in [37] . In addition, there is another important aspect that has never been taken into account and that is the simultaneous examination of the global picture and dynamics of the different Tregs subsets in the same patient. These subsets include HIV-specific, naïve and activated/memory circulating global Tregs. In this study we have delineated the dynamics of Tregs subsets after vaccination and IL-2 therapy, and according to previous studies (SILCAAT and ESPRIT phase III trials) [ + Tregs correlated positively with viral load after treatment interruption, which suggests that Tregs may represent a potential reservoir for the virus. Indeed, there is strong evidence that Tregs can become latently infected and may represent a potentially important HIV reservoir as i) they expand in blood and tissues in chronically HIV-infected patients and SIV-infected macaques [39] ; ii) HIV/SIV DNA levels in Tregs from HIV-infected patients on HAART and SIV-infected rhesus macaques are higher than that of non-Tregs [40, 41] ; and iii) Tregs are less susceptible to cell death than conventional T cells [39] . As such, therapeutic interventions aiming at Tregs depletion may directly contribute to the reduction of the size of virus reservoir [42] . In addition, IL-2 signaling through CD25 facilitates HIV replication in vitro and facilitates homeostatic proliferation of CD25 lated with viral load after treatment interruption. These data are in line with previous LCMV mouse studies, where daily therapeutic low-dose IL-2 increased virus-specific T-cell responses, thus resulting in decreased viral burden [43] . There must be a slow turnover of circulating Tregs that are constantly dividing as their absolute number remains constant [44] . It needs to be clarified whether their survival and function relies solely on IL-2. One possible explanation to our results showing a significant increase in global Tregs compared to HIV-specific Tregs after vaccination and IL-2 therapy could be the fact that the former can be exclusively dependent on IL-2 for expansion, survival and function, whereas the latter are largely controlled by signaling through the TCR for their generation. This could explain their role in controlling HIV-specific responses without relying that much on IL-2 for their function. Indeed, these hypotheses need to be verified in our future investigations.
We have previously shown in Dalia1 clinical study [45] that CD4 + CD25 + CD134 + HIVspecific responses induced after vaccination, inversely correlated with viral load rebound after treatment interruption [9] . Similar outcomes were found here in ANRS 093 study, where we measured CD4 + HIV-specific responses at wk0, wk16 and wk36 using the "OX40 assay". In the primary ANRS 093 study [30] , we have reported that HIV-specific immune responses at wk0, before therapeutic vaccination and IL-2 administration, did not correlate with the control of viral replication following TI in contrast to wk16 responses. In the present study we extend these data, and support the role of IL-2 in boosting pre-existing HIV-specific effector T cells and suggest its use as an adjuvant in combination with an efficient HIVvaccine. correlated with viral load confirming the non-beneficial role of HIV-specific Tregs in the context of therapeutic vaccination [9] . Altogether, these data uncover some benefits in the use of IL-2 as an adjuvant in HIV-vaccines protocols.
Given that therapeutic vaccines and cytokines have been commonly used to enhance HIVspecific cell-mediated immune responses and to suppress virus replication, revisiting IL-2 for its use as an adjuvant in HIV therapeutic vaccination, appears timely. While the former is important to stimulate HIV-specific T-cell responses, the latter may support the expansion of the stimulated virus-specific T cells. The recent success using checkpoints inhibitors in the cancer field [46] , have started to be introduced in preclinical models of HIV with the objective to preserve the function of HIV-specific CD8 + T cells from exhaustion and target directly HIV cell reservoir [47] [48] [49] . These major advances in immunological intervention strategies provide a rationale for revisiting the use of IL-2 together with immune checkpoint molecules in combinatorial therapeutic strategies to enhance the vaccine-elicited immune response and thus gain more efficient control of virus replication (review in [50] ). Studies using the LCMV model indicated that combined IL-2 and PD-1 blockade therapy represents a promising therapy for increasing CD8 T cell function and reducing viral loads during chronic infection [43] . Additional studies will need to be performed to determine whether IL-2 or combined IL-2 therapy helps "reprogram" exhausted CD8 T cells in humans.
Altogether our data highlight the positive role of IL-2 therapy in HIV infection, as despite an increase in CD25 + CD127
low Tregs, HIV-specific effector CD4 + T cells were greatly increased and were able to reduce viral load. This emphasizes the distinct roles that IL-2 therapy can have during an autoimmune manifestation where low-dose IL-2 therapy can increase Tregs, resulting in clinical improvement (reviewed in [22] ) and during chronic infection where virus-specific T cells can expand and impact on viral load. Thus combining IL-2 therapy with vaccination seem to be promising and useful in clinical strategy for reversing T cell exhaustion during chronic infections and boosting antigen-specific effector responses leading to an enhanced reduction in viral burden.
Materials and methods
Patients, vaccines and study design
Seventy patients over 18 years, with asymptomatic HIV-1 infection and CD4 T-cell counts > 350 cells/ml and plasma HIV RNA < 50 copies/ml and who have been previously treated with HAART for at least 1 year were eligible. Patients who received subcutaneous IL-2 in a previous study [31] , were also eligible and the last cycle was administered at least 3 months prior study entry. Patients were randomized to continue either HAART alone (n = 37; control group) or combined with 10 6.6 median infectious dose (ID50) ALVAC vCP 1433 and 3 mg HIV-LIPO-6T (both given by Aventis Pasteur) administered intramuscularly at weeks 0, 4, 8, 12 followed by three cycles of subcutaneous IL-2 (given by Chiron Europe) at weeks 16, 24, 32 (4.5 MIU, twice daily for 5 days) (n = 33; vaccine group) (Fig 1a) . ALVAC-HIV expresses several HIV genes: for gp120 (MN strain) and a part of the anchoring transmembrane region of gp41 (LAI strain); for the p55 polyprotein, expressed by gag (LAI strain); for a portion of pol encoding the protease; and for genes expressing cytotoxic T lymphocyte peptides from pol and nef. The HIV-LIPO-6T vaccine is a mixture of the tetanus toxoid TT-830-843 class IIrestricted universal CD4 epitope combined with five peptides: Gag 17-35, Gag 253-284, Nef 66-97, Nef 116-145 and Pol 325-355 from HIV-1 LAI. Patients with HIV RNA < 50 copies/ ml stopped HAART at week 40. Following treatment interruption, HAART was reinitiated if HIV RNA was > 50 000 cp/ml at 4 weeks after interruption or > 10 000 copies/ml at 8 weeks after interruption or thereafter at any protocol follow-up visit.
Blood samples
All experiments were performed on freshly thawed cells that were left to rest for 5-6 hours in human serum-supplemented medium at 37˚C.
Flow cytometry staining and phenotyping
All staining experiments were performed at 4˚C for 30 minutes. Antibodies used were CD3-PerCPCy5.5, CD3-AF700, CD4-Brilliant Violet 605, CD8-APC-Cy7, CD25-APC, CD134-PE, OX40-APC, TNF-α-PECy7, CD154-APC, CD152-PCF594, Tbet-PerCPCy5.5, PD1-PeCy7, CD15s-Brilliant Violet 421, Helios-PE, ICOS-PeCy7, CD39-Brilliant Violet 711 (Becton Dickinson (BD) Biosciences), CD4-Alexa Fluor 700, IFN-γ-eFluor450, IL2-PerCPeFluor710, Streptavidin-Alexa Fluor 700 (eBioscience), FoxP3-Alexa Fluor 488, CD25-Brilliant Violet 421 (BioLegend), CD39-biotin, CD127-PE, CD4-APCVio770, CD3-APCVio770 (Miltenyi biotec), Streptavidin-ECD, CD45RO-ECD (Beckman Coulter). LIVE/DEAD fixable aqua staining kit (Life technologies) was used to discriminate live and dead cells. For intracellular staining, FoxP3 buffer set (eBioscience) was used. Cell acquisition was performed by an LSR II (Becton Dickinson) and analyses were performed using FlowJo software.
T-cell functional assays
The "OX40 assay" is described in details elsewhere [9, 51] . Briefly, two million PBMCs or Tregs-depleted cells were plated in 24-well plate and stimulated with 1μg/mL CMV lysate (Behring) or 2μg/mL of HIV-1 Gag p24 peptide pool for 44 hours. In the last 6 hours, 1μg/mL of Brefeldin A (Sigma) was added to block the secretion of IFN-γ, IL-2 and TNF-α. Cells were then collected and stained for subsequent analysis by flow cytometry (BD LSR II).
In some experiments CD39 + CD4 + cells were depleted from PBMCs before performing the "OX40 assay". Briefly, we first isolated CD4+ T cells that were negatively selected using CD4 Microbeads (Miltenyi Biotec). The non-CD4 cell fraction has been collected too and put in a -depleted PBMCs). Hence, "OX40 assay" was then performed as described above on total PBMCs and on CD39+CD4+-depleted PBMCs.
EliSpot ELISpot assay
Evaluation of HIV-specific cells producing interferon-γ (IFN-γ) was assessed on frozen total PBMCs and CD39 + CD4 + -depleted PBMCs (obtained as described above) and using an ELI-SPOT assay performed as described [31] . Antigens included 9 or 18 pools of 15-mer peptides covering HIV-1 Gag (11 pools), reverse transcriptase (four pools) and Nef (three pools) (Neosystem) at 2 μg/ml. The IFN-γ-producing cells were counted using an automated microscope (Zeiss, Le Pecq, France), expressed as spot-forming cells (SFC)/10 6 PBMC and averaged over triplicate wells. The number of specific SFC/10 6 PBMC was calculated by subtracting the negative control value (unstimulated cells) from the established SFC count. Positive responses were defined as greater than 100 SFC/10 6 PBMC over background and at least twofold the background value. The breadth of the response was the number of recognized pools among 18 pools tested and the magnitude was defined as the sum of positive responses to individual pools (total SFC/10 6 PBMC).
Statistical analysis
Analyses of differences between pre-and post-vaccination time points were done by Wilcoxon matched-pairs signed rank test. Correlations were assessed by Spearman correlation coefficients. Prism 5.0, version 5.0d, (GraphPad Software, Inc.) was used for statistical analyses. P values were considered significant when < 0.05.
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